How is secukinumab dosed for plaque psoriasis?

Secukinumab 300 mg SC: loading at weeks 0, 1, 2, 3, 4 then monthly maintenance. 150 mg loading then monthly for patients achieving adequate response at 150 mg. PASI-90 achieved in 79% at week 52 (ERASURE). PASI-100 (completely clear) in 44% at week 52—significantly higher than adalimumab (24%) and ustekinumab (21%).

Is PASI-75 or PASI-90 the better treatment target for secukinumab?

Modern target is PASI-90 or better (IGA 0/1). PASI-75 was the historical standard, but secukinumab and other IL-17/IL-23 inhibitors now commonly achieve PASI-90 and PASI-100. Treat-to-target guidelines (EuroGuiDerm) recommend reassessing at week 16: if PASI-75 not achieved, switch biologic class; if PASI-75 but <PASI-90, dose optimize.

Secukinumab Plaque Psoriasis PASI Response Calculator

Calculate PASI score and determine secukinumab dosing (300 mg vs 150 mg) for moderate-severe plaque psoriasis, monitoring PASI-75, PASI-90, and PASI-100 response milestones.

Use the full interactive calculator below, or

Secukinumab Plaque Psoriasis PASI Response Calculator

Frequently Asked Questions

How is secukinumab dosed for plaque psoriasis?

Is PASI-75 or PASI-90 the better treatment target for secukinumab?